ALK and lung carcinoma: The identification of target gene alterations is an evolution for the lung cancer management, with the combination of tumor genotyping making personalized treatment possible, and it is of great benefit to patients treated with kinase inhibitors (TKIs) for EGFR, ALK, ROS1, BRAF, or MET (7–11).